SFRP5 and anaplastic large cell lymphoma: We confirmed that the combination treatment reduced the amount of β-catenin associated with SFRP5 induction in Karpas299 cells (Supplementary Figure S6), suggesting that targeting the Wnt/β-catenin pathway through SFRP5 induction is one of the molecular mechanisms of synergistic anti-ALCL effects.